(0.05%) 5 472.24 points
(0.07%) 39 140 points
(0.37%) 17 783 points
(-0.05%) $80.79
(-3.66%) $2.66
(-0.79%) $2 312.50
(0.25%) $28.94
(3.61%) $1 022.00
(0.29%) $0.936
(0.69%) $10.68
(0.46%) $0.792
(-0.27%) $87.25
Live Chart Being Loaded With Signals
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer...
Stats | |
---|---|
今日成交量 | 887 |
平均成交量 | 15 945 |
市值 | 26.67M |
EPS | $-0.540 ( Q1 | 2024-05-20 ) |
下一个收益日期 | ( $-1.130 ) 2024-08-19 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.430 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0840 (2.90%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-04 | Conley Mark William | Sell | 25 000 | Employee Stock Option (right to buy) |
2024-05-03 | Skyler Jay S | Buy | 0 | |
2024-02-21 | Kropotova Alexandra | Buy | 140 000 | Employee Stock Option (right to buy) |
2024-02-21 | Sullivan Eddie Joe | Buy | 190 000 | Employee Stock Option (right to buy) |
2024-02-21 | Bausch Christoph Lawrence | Buy | 140 000 | Employee Stock Option (right to buy) |
INSIDER POWER |
---|
69.75 |
Last 87 transactions |
Buy: 19 533 010 | Sell: 3 162 658 |
SAB Biotherapeutics, Inc. 财务报表
Annual | 2023 |
营收: | $2.24M |
毛利润: | $-1.51M (-67.28 %) |
EPS: | $-7.64 |
FY | 2023 |
营收: | $2.24M |
毛利润: | $-1.51M (-67.28 %) |
EPS: | $-7.64 |
FY | 2022 |
营收: | $23.90M |
毛利润: | $20.61M (86.23 %) |
EPS: | $-4.31 |
FY | 2021 |
营收: | $60.88M |
毛利润: | $0.00 (0.00 %) |
EPS: | $-0.394 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。